Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
92 Leser
Artikel bewerten:
(0)

Ortho Clinical Diagnostics' VITROS XT MicroSlide Receives CE Mark: First Multi-test Capability Added to Proprietary MicroSlide Technology


Groundbreaking Technology Delivers Accurate Results Clinicians Rely On and Trust While Simplifying Workflow and Improving Turnaround Time

RARITAN, New Jersey, March 13, 2019 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced it has received CE Mark for Ortho's VITROS XT MicroSlide, a new multi-test technology that allows labs to run two tests simultaneously.

Ortho Clinical Diagnostics' VITROS XT MicroSlide (right) is a new multi-test technology that allows labs to run two tests simultaneously.

Ortho's VITROS XT MicroSlide is powered by DIGITAL CHEMISTRY, an optics technology that gleans significantly more information from each test than before, improving performance, saving time and space in the lab, and increasing productivity, with less patient sample required for testing. This is an important advantage for vulnerable patients or those with venous access issues.

"Groundbreaking VITROS XT MicroSlides harness the power of our proprietary MicroSlide technology, delivering high-quality test results and higher throughput, all within the lab's existing physical footprint," said Jennifer Paine, Head of Business Fields at Ortho. "Performing two tests per slide reduces the sample volume over current technology. This approach allows timely reporting - especially important for complex, challenging or delicate patients."

Key features and benefits of Ortho's VITROS XT MicroSlide include:

  • DIGITAL CHEMISTRY: Advanced digital imaging optics technology that gleans significantly more information from each test than before, improving performance and enabling powerful data analysis.
  • Reliably high-quality results: Enable labs to consistently and efficiently deliver accurate and reliable results you trust.
  • Increased productivity and efficiency: Simultaneously perform two tests that are commonly ordered together from a single small blood sample. This improves lab productivity and turnaround time, while simplifying inventory management and optimizing storage space.

"The Ortho VITROS XT MicroSlide is a great technological leap, with DIGITAL CHEMISTRY signifying a true revolution in the pursuit of consistently reliable and accurate clinical diagnoses," said Dr. Jorge Aldunate Ortega, Clinical Laboratory Manager of RedSalud in Chile. "This technology reinforces Ortho as the trusted leader in the field of chemistry and immunodiagnostics."

Ortho's VITROS XT MicroSlides, which include VITROS UREA-CREA, TRIG-CHOL and GLU-Ca slides, have received CE Mark signifying conformance to applicable European Union regulatory requirements. These products are available on the VITROS XT 7600 Integrated System for purchase in March 2019. The product is currently available for purchase in numerous countries, including Chile, France, Germany, Hong Kong, Iceland, Italy, Spain, Switzerland, the UK, Australia, Liechtenstein, Norway and New Zealand.

For more information, follow Ortho on LinkedIn, Twitter, Facebook and Instagram.

About Ortho's VITROS Systems
The Ortho VITROS Chemistry, Immunodiagnostics and Integrated Systems from Ortho Clinical Diagnostics is a portfolio of products and patented enabling technologies which help clinical laboratories diagnose, monitor and treat disease. Ortho's VITROS Products are engineered to help clinical laboratories with organizational, operational and economic challenges.

About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.

© Ortho Clinical Diagnostics 2019

PR-04864

Photo - https://mma.prnewswire.com/media/829496/XT_Microslides_D.jpg


© 2019 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.